T. Nagatomo, Y. Hosohata, T. Ohnuki, Takashi Nakamura, K. Hattori, J. Suzuki, M. Ishiguro
{"title":"bopinddolol:药理基础和临床意义","authors":"T. Nagatomo, Y. Hosohata, T. Ohnuki, Takashi Nakamura, K. Hattori, J. Suzuki, M. Ishiguro","doi":"10.1111/J.1527-3466.2001.TB00180.X","DOIUrl":null,"url":null,"abstract":": Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":"96 1","pages":"9-24"},"PeriodicalIF":0.0000,"publicationDate":"2006-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Bopindolol: Pharmacological Basis and Clinical Implications\",\"authors\":\"T. Nagatomo, Y. Hosohata, T. Ohnuki, Takashi Nakamura, K. Hattori, J. Suzuki, M. Ishiguro\",\"doi\":\"10.1111/J.1527-3466.2001.TB00180.X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.\",\"PeriodicalId\":9490,\"journal\":{\"name\":\"Cardiovascular drug reviews\",\"volume\":\"96 1\",\"pages\":\"9-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular drug reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/J.1527-3466.2001.TB00180.X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1527-3466.2001.TB00180.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bopindolol: Pharmacological Basis and Clinical Implications
: Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.